Compare CSX Corporation (CSX) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

CSX trades at $50.27, down 0.85% on the day, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and 17% operating income increase. The company raised 2026 guidance to mid-to-high-single-digit revenue growth and margin expansion. Analyst consensus is bullish with 59% buy ratings and a $52.57 price target, implying 4.6% upside from current levels.

Outlook remains positive due to strong volume growth and operational efficiency, but risks include fuel cost pressures and economic sensitivity. The stock offers value through consistent dividends and earnings momentum, though valuation multiples appear elevated with P/E at 29.23. Investors should monitor execution against raised guidance and industry headwinds.

Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.

DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.